Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease
Authors not listed
Stemedica Cell Technologies, Inc. · 2016
Abstract
STUDY OBJECTIVES
Primary:
To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects with mild to moderate dementia due to Alzheimer's disease.
Secondary:
To assess the preliminary efficacy of hMSCs versus placebo in subjects with Alzheimer's-related dementia, as evidenced by neurologic, functional, and psychiatric endpoints.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2016). A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease. <em>Stemedica Cell Technologies, Inc.</em>. https://clinicaltrials.gov/study/NCT02833792
Vancouver
Anonymous. A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease. Stemedica Cell Technologies, Inc.. 2016.
BibTeX
@misc{anon2016APhase,
title = {A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease},
author = {Anonymous},
journal = {Stemedica Cell Technologies, Inc.},
year = {2016},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cell Death and Differentiation 2008
Citation only
Astroglia in dementia and Alzheimer's disease
AbbVie 2015
Open access · US-GOV
A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease
Springer eBooks 2015
Citation only
Prevention of Neurodegeneration for Alzheimer’s Disease by Lycium barbarum
Ageing Research Reviews 2013
Preprint · OA
Perturbations of neural circuitry in aging, mild cognitive impairment, and Alzheimer's disease
The Lancet 2021
Preprint · OA
Alzheimer's disease
Handbook of clinical neurology 2019
Citation only